FMC price target lowered to $15.50 from $17 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on FMC (FMC) to $15.50 from $17 and keeps an Equal Weight rating on the shares. The firm lowered its estimates but maintains the view that the most likely outcome for FMC is some form of a joint venture or license agreement on its four new patented molecules, though this could also include co-development of the balance of the R&D pipeline.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas” class=”link “>Try Now>>

>;elm:context_link;itc:0;sec:content-canvas” class=”link “>See today’s best-performing stocks on TipRanks >>

Read More on FMC:

Disclaimer & DisclosureReport an Issue

• FMC price target lowered to $14 from $16 at RBC Capital

• FMC price target lowered to $14 from $15 at UBS

• FMC price target lowered to $14 from $16 at Wells Fargo

• FMC falls -20.1%

• FMC sees FY26 adjusted EPS $1.63-$1.89, consensus $2.44